VivoSeq
Oncology

Anatomic Stage 0 Breast Cancer AJCC V8

5

Pipeline Programs↗

2

Active Trials↗

3

Companies Involved↗

Anatomic Stage 0 Breast Cancer AJCC v8 is an early-stage landscape with 5 programs across 3 companies. The most active players are Novartis, Pfizer, AstraZeneca. 5 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

29/100

Pipeline Velocity

6/100

Mech. Concentration

75/100

Completion Rate

0/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

1 program

Phase 3Pfizer logo

Pfizer

1 program

Phase 3AstraZeneca logo

AstraZeneca

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

3

clinical trials

Not yet recruiting1 · 33%
Suspended1 · 33%
Active, not recruiting1 · 33%

Clinical Trials

Trial Activity

Implementation of a Navigation Program for Breast Cancer Survivors
Not yet recruiting·OOhio State University Comprehensive Cancer Center·Preclinical·NCT07699991·330 enrolled
LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients With Molecular Low-Risk Early-Stage Breast Cancer
Suspended·Alliance for Clinical Trials in Oncology·Phase 3·NCT06671912·1,556 enrolled
Prospective Evaluation of a Once Per Day Regimen of Accelerated Partial Breast Irradiation in Low-Risk, Hormone-Responsive Breast Cancer
Active, not recruiting·CCity of Hope Medical Center·Phase 2·NCT06008158·48 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)